SEC Form 4
------------

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

	OMB Number:	3235-0287							
Estimated average burden									
	hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addre		g Person <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol Arcturus Therapeutics Holdings Inc. [ARCT		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Markels John			]	X	Director	10% Owner				
(Last)	(First) US THERAP	(Middle) EUTICS HOLDINGS	3. Date of Earliest Transaction (Month/Day/Year) 08/01/2023		Officer (give title below)	Other (specify below)				
INC.			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)						
10628 SCIENC	CE CENTER	DRIVE, SUITE 250		X	Form filed by One Reporting Person					
(Street)					Form filed by More the Person	an One Reporting				
SAN DIEGO	CA	92121	Rule 10b5-1(c) Transaction Indication							
(City)	(State)	(Zip)	Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See In	hat a transaction was made pursuant to a contract, instruction or written plan that is intended to se conditions of Rule 10b5-1(c). See Instruction 10.						
		Table I - Non-Deriv	ative Securities Acquired, Disposed of, or Benef	icially	Owned					

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (II 8)		4. Securities Disposed Of 5)			Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (II 8)		n of Ex		6. Date Exerc Expiration Da (Month/Day/)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock option (right to buy)	\$34.92	08/01/2023		A		11,869		(1)	08/01/2033	Common Stock	11,869	\$0.00	11,869	D	
Deferred Stock Units	(2)	08/01/2023		A		3,131		(3)	(3)	Common Stock	3,131	\$0.00	3,131	D	

## Explanation of Responses:

1. Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

2. Each deferred stock unit is economically equivalent to one share of the Issuer's common stock.

3. Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

/s/ Ilan Katz, attorney-in-fact 08/03/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.